Related Experiment Videos
[Neuromyeloencephalopathy caused by high-dose muzolimine medication in patients with renal failure]
B Pohlmann-Eden1, P Berlit, A Holle
1Neurologische Klinik, Klinische Fakultät Mannheim, Ruprecht-Karls-Universität Heidelberg.
Abstract:
We report on 7 patients suffering from chronic renal failure (2 females, 5 males; aged 35-75 (phi 53.5) years) who showed severe neuromyeloencephalopathy (NME) after high doses of a new Henle's loop diuretic, Muzolimine. The temporal and phenomenological development of these systems was strikingly parallel. The neurological deficit was revealed on neurophysiological, neuroradiological and in 2 cases on neuropathological tests (gross demyelinisation of the posterior column, mainly of the fasciculus gracilis, less in the lateral corticospinal tract and in some spinal roots). The critical drug dose for first neurological impairment was 52 g on average; at this point the patients had been treated for 78 days. The maximal daily dose was 1.440 mg. Dominant clinical features were pallhypaesthesia, ataxia, signs of peripheral neuropathy in combination with hyperreflexia and progressive para- to tetraspastic paresis. Constellation of symptoms, course of disease and findings of additional investigations, especially those of neuropathology, very much resemble Vitamin B12 deficiency and SMON-(Subacute Myelo Optic Neuropathy) syndrome. The rare entity of Muzolimine-NME is discussed in respect to other endogenous and exotoxic neuromyelopathies. We present the hypothesis of a toxic, partially dialysable metabolite of Muzolimine.
Insights
High doses of Muzolimine, a new diuretic, caused severe neuromyeloencephalopathy (NME) in patients with chronic renal failure. Symptoms resembled Vitamin B12 deficiency and Subacute Myelo Optic Neuropathy (SMON).
Area of Science:
- Nephrology
- Neurology
- Toxicology
Background:
- Chronic renal failure patients are susceptible to drug-induced neurological complications.
- Henle's loop diuretics can have diverse physiological effects.
Observation:
- Seven patients with chronic renal failure developed severe neuromyeloencephalopathy (NME) after high-dose Muzolimine therapy.
- Neurological deficits included sensory impairment, ataxia, peripheral neuropathy, and progressive spastic paresis.
- Neuropathological findings revealed significant demyelination in the spinal cord posterior columns and tracts.
Findings:
- A critical average dose of 52g Muzolimine (over 78 days) was linked to initial neurological impairment.
- Clinical presentation and neuropathology closely mimicked Vitamin B12 deficiency and Subacute Myelo Optic Neuropathy (SMON).
- A hypothesis of a toxic, partially dialyzable Muzolimine metabolite causing NME is proposed.
Implications:
- Highlights the potential neurotoxicity of Muzolimine, particularly in renally impaired patients.
- Suggests careful monitoring for neurological symptoms during high-dose Muzolimine treatment.
- Warrants further research into Muzolimine's metabolic pathways and toxicological profile.